A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Australia

Prince of Wales Hospital, Randwick, New South Wales

Illawarra Cancer care centre, Wollongong Hospital, Wollongong, New South Wales